Dose-matched Placebo to Suvorexant

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

InsomniaPrimary Insomnia

Phase 2

Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)

CompletedNCT00792298

Merck Sharp & Dohme LLCPrimary Insomnia

Start: 2008-11-05End: 2009-12-26Updated: 2018-11-06

Phase 3

A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

CompletedNCT01021813

Merck Sharp & Dohme LLCInsomnia

Start: 2009-12-10End: 2011-08-01Updated: 2018-09-21

Related Papers

Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.

2017-03-0847 citations

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.

2017-03-0715 citations

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

2014-03-27234 citations